SOURCE: Rheologics Technologies, Inc.

April 10, 2007 08:30 ET

Rheologics Adds New Management -- Mark Daugherty as Financial Controller

New Controller Skills and Experience Will Strengthen Company's Growth and Ongoing Financial Preparedness

EXTON, PA -- (MARKET WIRE) -- April 10, 2007 -- Rheologics Technologies, Inc., ("Rheologics" or the "Company") (PINKSHEETS: RTGI), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces today the addition of a new member to its management team, Mark H. Daugherty, as Financial Controller. In moving its business plan forward, Rheologics is continuously expanding and improving its ongoing R&D, laboratory services and revenue opportunities, each of which poses new challenges and opportunities for the future that a financial controller with Daugherty's experience is well-suited to address.

Rheologics' Chairman & Chief Scientific Officer, Dr. Kenneth Kensey, stated: "Up to now, Rheologics has ensured sound financial maintenance but as the Company continues to lay its foundation for the future as a leader in the development and commercialization of innovative medical technologies, we recognize the need to hire a designated expert who can precisely manage Rheologics' financial transitions."

Mark H. Daugherty

Mark joins Rheologics' management team after years of effectively managing separate business partnerships for Kenneth R. Kensey, MD, Rheologics' Chairman & Chief Scientific Officer.

Mark has over 25 years experience in financial services and brings extensive management background, including finance, banking and administrative skills developed in previous positions. He was the top financial executive for three previous employers with extensive experience in financial statement analysis, strategic planning, budgeting, forecasting and the presentation of the results to Senior Management and the Board of Directors. Mark holds a BS in Business Administration and Accounting.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information

  • Contact:
    Daniel Cho

    ALLK Co.
    Media Contact
    Samantha Freire
    Email: Email Contact